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Received April 9, 2013; accepted October 24, 2013AbstractBackground: Bilateral salpingo-oophorectomy (BSO) is standardly performed in the treatment of endometrial cancer. The purpose of this study
was to evaluate the impact of ovarian preservation on the outcome of patients with endometrial cancer.
Methods: A retrospective cohort study was performed using the 2000e2010 database of endometrial cancer patients who were treated at Taipei
Veterans General Hospital. Information regarding patient age, pathologic reports, and follow-up results was abstracted from medical records.
Results: Five hundred and twenty-nine patients were reviewed in this study. Mean age and follow-up duration were 55.7  11.4 years and
37.5  30.1 months, respectively. The median disease-free survival was 31.2 months (range 0.2e126.9 months). There were no significant
differences in disease-free survival between stage I patients with ovarian preservation versus those with oophorectomy (p ¼ 0.473). In a
multivariate Cox model, ovarian preservation had no effect on disease-free survival [hazard ratio (HR) ¼ 2.72; 95% confidence interval (CI),
0.48e15.59]; however, it was not significantly related to stage and para-aortic lymph node involvement.
Conclusion: Ovarian preservation may be considered in premenopausal women with early-stage low-risk endometrial cancer.
Copyright  2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Endometrial cancer is the most common gynecologic ma-
lignancy in the United States, with 43,470 new cases and 7950
deaths estimated in 2010, ranking eighth for cancer-related
deaths.1 Endometrial cancer is traditionally considered a dis-
ease of postmenopausal women. However, previous research
has suggested that up to 14% of women with endometrial
cancer are premenopausal.2 According to the annual report of
the Department of Health in Taiwan, there were 1424 newly
diagnosed cases in 2008, and the incidence rate then increasedConflicts of interest: The authors declare that there are no conflicts of interest
related to the subject matter or materials discussed in this article.
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1726-4901/Copyright  2014 Elsevier Taiwan LLC and the Chinese Medical Assto 9.75 per 100,000.3 More than 30% of cases occurred in a
premenopausal state, and the incidence of disease in women
under the age of 45 years was 11%.3
Total abdominal hysterectomy, bilateral salpingo-
oophorectomy (BSO), and surgical staging are usually per-
formed in the treatment of endometrial cancer.2 Further treatment
is tailored according to the presence or absence of various risk
factors. This treatment policy has not been changed since 1988,
although numerous trials have been conducted.As such, BSO has
been recommended routinely, irrespective of the patient’s age.
BSO is aimed at excluding occult ovarian metastases and
decreasing estrogen production; however, the procedure results
in surgical menopause and places patients at risk for the long-
term sequelae of estrogen deprivation.2
The International Federation of Gynecology and Obstetrics
(FIGO) staging system for the endometrium was revised in
2009. The purpose of the staging system is to provide theociation. All rights reserved.
380 H.-Y. Lau et al. / Journal of the Chinese Medical Association 77 (2014) 379e384patient with an appropriate prognosis, which would result in
treatment improvement. Therefore, reappraisal of existing
treatment guidelines, even those that have been accepted for
decades, sometimes becomes necessary to determine whether
they are based on reliable evidence or hold true in the face of
new research.
Many studies have found that young women with endo-
metrial cancer have a more favorable prognosis than older
patients. Premenopausal women with endometrial cancer often
have low-grade, early-stage tumors that may in part explain
the differential survival.4e10 Therefore, the issue of ovarian
preservation in young women should be one that requires
further consideration; however, a largely unanswered question
is what the adverse effect of ovarian preservation in endo-
metrial cancer might be. The goal of this study was to deter-
mine the impact of ovarian preservation on the outcome of
patients with endometrial carcinoma.
2. Methods
With institutional review board approval (VGHIRB No:
2012-04-028AC), a retrospective cohort study in Taipei Vet-
erans General Hospital, Taipei, Taiwan reviewed the data of
patients with a final diagnosis of endometrial cancer between
2000 and 2010.
Medical charts, including admission and discharge notes, as
well as surgical pathology reports and radiation records, were
reviewed, and histological data [stage, grade, lymph vascular
space invasion (LVSI), depth of myometrial invasion, and
lymph node involvement], as well as survival data (disease-free
survival and overall survival) were extracted. All histological
material had been confirmed by gynecologic pathologists.
Disease-free survival was calculated as the number of months
from cancer diagnosis to date of recurrence or last follow-up.
Tumor staging was in accordance with the 1988 FIGO stag-
ing system and was based on available pathologic findings.
Unevaluated areas such as adnexa and lymph node status were
considered negative for metastatic disease.
The outcome among categorical variables was compared
using the c2 test. Cox regression models were developed to
describe predictors of risk factors for disease-free survival.
The KaplaneMeier test was used for survival analysis. A p
value < 0.05 was considered statistically significant. All an-
alyses were carried out using SPSS version 17 software (SPSS
Inc., Chicago, IL, USA).
3. Results
A total of 529 patients were evaluated. Ovarian preserva-
tion surgery was performed in 17 of the 529 patients. The
patients’ mean age and follow-up duration were
55.7  11.4 years (range 24.6e90.5 years) and
37.5  30.1 months, respectively. The median disease-free
survival was 31.2 months (range 0.2e126.9 months). The
clinical and histological characteristics are listed in Table 1.
The patients who had ovarian preservation were younger than
those who had oophorectomy (p < 0.001). Small tumor size(p ¼ 0.010), low-grade (p < 0.001), no pelvic lymph node
(p < 0.001), and no para-aortic lymph node (p < 0.001)
involvement were common in patients who had ovarian pres-
ervation. Stage I tumors were found in 100% of those who had
ovarian preservation versus 77.1% of women who underwent
oophorectomy (p ¼ 0.173).
Of the 17 patients with ovarian preservation surgery, 11
expressed the desire for ovarian preservation and six had other
preoperative diagnoses, e.g., endometrial hyperplasia, leio-
myoma, adenomyosis, or uterine prolapse. After pathologic
and postoperative image evaluation, stage I and endometrioid-
type tumors were found in all patients who had ovarian
preservation. No further surgery was undertaken in the patients
whose ovaries were saved incidentally, and two received
adjuvant radiotherapy. There was no significant difference in
disease-free survival in patients within the desire for ovarian
preservation group (median 39.8 months) and the incidental
ovarian preservation group (median 47.0 months; p ¼ 0.749).
Using univariate analysis, we found that disease-free sur-
vival was associated with potential risk factors including age
(p ¼ 0.011), tumor size (p ¼ 0.012), stage (I vs. II, p < 0.001;
I vs. III, p < 0.001; I vs. IV, p ¼ 0.006), tumor grade (1 vs. 2,
p < 0.001; 1 vs. 3, p < 0.001), myometrial invasion (super-
ficial vs. <1/2, p ¼ 0.002; superficial vs. 1/2, p < 0.001),
lymph vascular space invasion (p < 0.001), pelvic and para-
aortic lymph node-involvement (p < 0.001); however, it was
not significantly related to ovarian preservation (p ¼ 0.472;
Table 2). There were no significant differences in disease-free
survival between patients with ovarian preservation and those
with oophorectomy (p ¼ 0.277). Compared to the patients in
stage I of ovarian preservation and oophorectomy, there was
no significant difference in disease-free survival (median
21.1 months vs. 33.4 months; p ¼ 0.473, log-rank statistic;
Fig. 1). No metachronous ovarian malignancies were observed
during follow-up.
Multivariate Cox regression analysis was carried out for the
following variables: age, tumor size, stage, histological type,
tumor grade, depth of myometrial invasion, lymph vascular
space invasion, pelvic lymph node involvement, and para-
aortic lymph node involvement. Ovarian preservation
showed no statistically significant association with disease-
free survival [hazard ratio (HR) ¼ 2.72; 95% confidence in-
terval (CI), 0.48e15.59; p ¼ 0.671]. However, it was not
significantly related to stage I versus stage IV (HR ¼ 0.25;
95% CI, 0.12e0.54, p < 0.001) and para-aortic lymph node
involvement (HR ¼ 2.00; 95% CI, 1.06e3.75; p ¼ 0.032).
4. Discussion
Our review found that advanced stage and para-aortic
lymph node involvement were significant factors related to
disease-free survival. Ovarian preservation had no effect on
survival.
In our study, ovarian preservation was more commonly
performed in patients with small tumor size, endometrioid-
type, low-grade, and early-stage tumors. The median
disease-free survival was 21.1 months. Comparing patients
Table 1
Clinical and histological characteristics.
Characteristics No. of patients (n ¼ 529) Ovarian preservation (n ¼ 17) Oophorectomy (n ¼ 512) p
Mean age (y) 55.7  11.4 (24.6e90.5) 41.8  11.2 (24.6e61.5) 56.2  11.2 (26.2e90.5) <0.001
Mean tumor size (cm) 2.5  2.4 (0e18.0) 0.97  1.3 (0e3.5) 2.52  2.5 (0e18.0) 0.010
Stage 0.173
I 412 (77.9) 17 (100) 395 (77.1)
II 48 (9.1) 0 48 (9.4)
III 53 (10.0) 0 53 (10.4)
IV 16 (3.0) 0 16 (3.1)
Histology 0.361
Endometrioid 474 (89.6) 17 (100) 457 (89.2)
Nonendometrioid 24 (4.5) 0 24 (4.7)
Others 31 (5.9) 0 31 (6.1)
Tumor grade <0.001
1 150 (28.4) 8 (47.1) 142 (27.7)
2 296 (55.9) 8 (47.1) 288 (56.3)
3 82 (15.5) 1 (5.8) 81 (15.8)
N/A 1 (0.2) 0 1 (0.2)
Myometrial invasion 0.162
Superficial 79 (14.9) 5 (29.4) 74 (14.5)
<1/2 320 (60.5) 10 (58.8) 310 (60.5)
>1/2 130 (24.6) 2 (11.8) 128 (25.0)
Lymphevascular space invasion 1.000
No 449 (84.9) 15 (88.2) 434 (84.8)
Yes 80 (15.1) 2 (11.8) 78 (15.2)
Pelvic lymph node involvement <0.001
No 482 (91.1) 17 (100) 465 (90.8)
Yes 47 (8.9) 0 47 (9.2)
Para-aortic lymph node involvement <0.001
No 498 (94.1) 17 (100) 481 (93.9)
Yes 31 (5.9) 0 31 (6.1)
Recurrence 0.618
No 494 (93.4) 17 (100) 477 (93.2)
Yes 35 (6.6) 0 35 (6.8)
Data are presented as n (range) or n (%).
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preservation, there were no statistically significant differences.
Therefore, ovarian preservation may be feasible and safe with
early-stage and low-grade endometrial cancer.
Since the change in FIGO guidelines for endometrial can-
cer staging in 1988,11 there has been controversy regarding the
necessity of aggressive surgical staging, including BSO and
lymphadenectomy, particularly in young women with early-
stage disease. In addition to the immediate consequences of
hot flashes and vaginal atrophy with BSO, surgical menopause
in young women results in a number of long-term sequelae,
including an increased risk of cardiovascular disease, osteo-
porosis, hip fracture, and cognitive dysfunction.12 Rosenberg
et al13 reported that the risk of myocardial infarction is
increased more than seven-fold in those who undergo bilateral
oophorectomy prior to the age of 35 years. Several studies
reported that early oophorectomy seems to have a direct effect
on all-cause mortality.14 Parker et al15 demonstrated that
women who have oophorectomy prior to the age of 55 years
have 8.6% excess mortality by the age of 80 years, and those
with oophorectomy prior to age 59 years have 3.92% excess
mortality. A prospective, population-based cohort study found
that women who underwent prophylactic bilateral oophorec-
tomy prior to the age of 45 years had a 67% increase inmortality.16 Thus, to avoid the short- and long-term conse-
quences of surgical menopause, there is a strong rationale for
ovarian preservation in young women.
The rationale for performing oophorectomy in women with
endometrial cancer is based on two theoretical risks. First,
estrogen production from the ovaries may stimulate micro-
scopic foci of residual endometrial cancer; second, there may
be a coexisting synchronous primary tumor within the ovaries.
Theoretically, estrogen stimulates the growth of endometrial
cancer cells and upregulates the expression of estrogen re-
ceptors. However, several studies have been unable to
demonstrate an increase in the risk of recurrence or death in
women receiving estrogen replacement.17e19 The largest study
[Gynecologic Oncology Group (GOG) No. 317] was a pro-
spective trial of estrogen replacement therapy in more than
1200 women with endometrial cancer. Although the trial
ended early, the absolute recurrence rate was 2.1%
(HR ¼ 1.27; 95% CI, 0.92e1.77) and the incidence of new
malignancy was low.17
Synchronous primary tumors of the endometrium and ovary
occur in approximately 5% of all women with endometrial
cancer.20 Walsh et al21 reported a series of 102 women
younger than 45 years with endometrial cancer. Twenty-six
patients (25%) had coexisting epithelial ovarian tumorsd23
Table 2
Cox regression model of factors associated with disease-free survival.
Univariate Multivariate
HR 95% CI p HR 95% CI p
Ovarian preservation
No Reference Reference
Yes 0.35 0.08e1.45 0.472 2.72 0.48e15.59 0.671
Age (y)
60 Reference Reference
>60 2.37 1.22e4.59 0.011 1.10 0.89e1.35 0.361
Tumor size
<2 cm Reference Reference
2 cm 2.75 1.25e0.65 0.012 1.15 0.95e1.40 0.154
Stage
I Reference Reference
II 0.02 0.08e0.70 <0.001 0.51 0.21e1.22 0.128
III 0.03 0.01e0.16 <0.001 0.42 0.17e1.04 0.062
IV 0.23 0.08e0.66 0.006 0.25 0.12e0.54 <0.001
Histology
Endometrioid Reference Reference
Nonendometrioid 0.35 0.12e1.02 0.054 1.07 0.71e1.61 0.738
Others 1.95 0.55e6.94 0.301 1.01 0.53e1.90 0.984
Tumor grade
1 Reference Reference
2 0.06 0.02e0.21 <0.001 0.30 0.07e1.32 0.112
3 0.28 0.14e0.54 <0.001 0.71 0.31e1.63 0.420
Myometrial invasion
Superficial Reference Reference
<1/2 0.04 0.01e0.30 0.002 1.08 0.76e1.53 0.678
1/2 0.20 0.10e0.40 <0.001 1.20 0.93e1.54 0.160
Lymphevascular space invasion
No Reference Reference
Yes 8.45 4.33e16.52 <0.001 1.30 0.93e1.81 0.121
Pelvic lymph node involvement
No Reference Reference
Yes 6.39 3.12e13.1 <0.001 1.35 0.71e2.56 0.366
Para-aortic lymph node involvement
No Reference Reference
Yes 8.18 3.66e18.30 <0.001 2.00 1.06e3.75 0.032
CI ¼ confidence interval; HR ¼ hazard ratio.
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metastatic. Preoperative ovarian imaging of the women with
ovarian involvement was normal in 15% of patients. Of those
with ovarian tumors, 15% had normal-appearing adnexa
intraoperatively. Pan et al22 reported that the incidence of
coexisting ovarian cancer in clinical stage I endometrial
carcinoma was low, but 50% (10 of 20) of the ovarian tumors
had microscopic ovarian involvement. The authors of these
studies recommended a cautious approach when considering
ovarian preservation in young women. Despite the potential
for occult ovarian tumors in women who undergo ovarian
preservation, we found that outcome and survival were not
compromised.
Several studies have been conducted to evaluate the safety
of ovarian preservation. Wright et al2 found that ovarian
preservation had no effect on either cancer-specific
(HR ¼ 0.58, 95% CI, 0.14e2.44) or overall (HR ¼ 0.68,
95% CI, 0.34e1.35) survival. Koskas et al23 reported that in
184 patients with grade 1 intramucous endometrial adeno-
carcinoma, ovarian preservation was not associated with anincrease in cancer-related mortality. However, longer follow-
up is needed to confirm the safety of a conservative
approach toward the ovaries. In our study, there was no sig-
nificant difference in disease-free survival in stage I patients
with ovarian preservation and those with oophorectomy
(p ¼ 0.473). Disease-free survival was not associated with
ovarian preservation. Advanced stage and para-aortic lymph
node involvement were significant factors related to patient
outcome. Multivariate Cox regression analysis revealed that
the most important factors associated with disease-free sur-
vival were stage I versus stage IV (HR ¼ 0.25, 95% CI,
0.12e0.54) and para-aortic lymph node involvement
(HR ¼ 2.00, 95% CI, 1.06e3.75). Para-aortic lymph node
involvement had a more than two-fold effect on disease-free
survival (14.2 months vs. 33.4 months, p < 0.001). The me-
dian survivals for stage I, stage II, stage III, and stage IV
disease were 40.2 months, 36.8 months, 23.2 months, and
17.6 months, respectively.
Our results are similar to those of a previous study.24 We
found that early-stage disease had a favorable prognosis.
Fig. 1. Disease-free survival in stage I patients with ovarian preservation and
oophorectomy. The disease-free survival of patients with ovarian preservation
(median 21.1 months) was similar to that of the patients with oophorectomy
(median 33.4 months; p ¼ 0.473).
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cal type of carcinoma (serous carcinoma and clear-cell carci-
nomas were poor prognostic types), histological grade, stage
of disease, depth of myometrial invasion, LVSI, and cervical
involvement, had prognostic importance. However, our find-
ings are notable in that ovarian preservation did not adversely
impact the recurrence of endometrial cancer. Advanced stage
and para-aortic lymph node involvement had a more signifi-
cant impact on survival. Therefore, ovarian preservation in
premenopausal women with early-stage endometrial cancer
may be considered.
Some limitations of this study should be kept in mind when
interpreting our results. This was a retrospective study with a
low number of cases and ethical considerations. A randomized
controlled trial will be conducted to determine the equivalency
of ovarian preservation and BSO. Although our survival esti-
mates suggest that ovarian preservation does not negatively
impact outcome, the less than 5-year disease-free follow-up
interval may not be sufficient to guarantee patient survival. It
should be recognized that, based on the 95% CIs that we
calculated, ovarian preservation may be associated with a two-
fold increase in morbidity. It is therefore imperative that these
findings be conveyed in the proper context when counseling
patients.
In conclusion, our findings report that ovarian preserva-
tion does not adversely impact incidence of recurrence and
disease-free survival. Ovarian preservation may be consid-
ered in premenopausal women with early-stage and low-risk
endometrial cancer. However, preservation of the ovariesshould be approached cautiously and consideration given to
the patient’s desire after providing a full explanation of
the potential risks. The long-term risks and benefits of
ovarian preservation should be carefully discussed with the
patient.
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